Product

AGEN2373

Aliases

Anti-CD137

1 clinical trial

1 indication

Indication

Advanced Cancer

Clinical trial

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer

Status: Active (not recruiting), Estimated PCD: 2025-06-01